semaglutide and cardiovascular outcomes in obesity without diabetes journal club Diabetes: The SELECT Trial Insights into semaglutide cardiovascular research:

A generic version of semaglutide, more commonly known by the brand name Ozempic, is now available in Canada as patent protections expire

MedlinePlus warns that intramuscular injection site selection is important because you do not want to hit a nerve or blood vessel

The National Institutes of Health (NIH) warns that chronic alcohol users are particularly vulnerable to acetaminophen-induced liver injury, making it essential to avoid alcohol while taking the medication

Single-cell immune profiling of Meniere disease patients

This may include adjusting the timing of medication intake, ensuring adequate hydration, dietary modifications, and over-the-counter medications

Translational perspective for the use of dual GLP-1R/GcgR agonists for obesity Multiple clinical trials involving GLP-1R/GcgR co-agonists are currently underway (Table 1)